

## Appendix 4G – Corporate Governance Statement

**Melbourne, Australia; 24 August 2023:** Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Appendix 4G – Key to Disclosures Corporate Governance Council Principles and Recommendations, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.

---

### About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications. As an innovative Australian biopharmaceutical company, Starpharma is focussed on developing and commercialising novel therapeutic products that address significant global healthcare needs. Starpharma boasts a strong portfolio of products, partnerships, and intellectual property.

Starpharma's innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.

Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing pharmaceuticals. Starpharma's portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced Product ("DEP<sup>®</sup>") drug delivery technology, and marketed products, including VIRALEZE<sup>™</sup> and VivaGel<sup>®</sup> BV, which utilise SPL7013, a proprietary dendrimer with antimicrobial properties.

Starpharma's DEP<sup>®</sup> drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to reduce drug-related toxicities through controlled and specified drug delivery.

In addition to Starpharma's internal DEP<sup>®</sup> programs, Starpharma has multiple DEP<sup>®</sup> partnerships with international biopharmaceutical companies, including AstraZeneca (oncology); MSD (Antibody-Drug Conjugates); Chase Sun (anti-infectives); and other world-leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma's DEP<sup>®</sup> platform, partnered DEP<sup>®</sup> programs have the potential to generate significant future milestones and royalties.

Starpharma's topical antiviral nasal spray, VIRALEZE<sup>™</sup>, is now registered in more than 35 countries\*, including Europe, the UK, and Asia. Starpharma's novel non-antibiotic vaginal gel, VivaGel<sup>®</sup> BV, for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV, is registered in more than 50 countries, including in the UK, Europe, Southeast Asia, South Africa, Australia and New Zealand.

For more information about Starpharma, visit [www.starpharma.com](http://www.starpharma.com) or connect with Starpharma on [LinkedIn](#).

---

### Media: Sumit Media

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

### Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer  
Justin Cahill, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

### Disclosure

This ASX Announcement was authorised for release by the Board of Directors.

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", "outlook", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.

# Appendix 4G

## Key to Disclosures

### Corporate Governance Council Principles and Recommendations

Name of entity

Starpharma Holdings Limited
-----------------------------

ABN/ARBN

20 078 532 180
----------------

Financial year ended:

30 June 2023
--------------

Our corporate governance statement<sup>1</sup> for the period above can be found at:<sup>2</sup>

- These pages of our annual report:
- This URL on our website: [http://www.starpharma.com/corporate\\_governance](http://www.starpharma.com/corporate_governance)

The Corporate Governance Statement is accurate and up to date as at 24 August 2023 and has been approved by the Board.

The annexure includes a key to where our corporate governance disclosures can be located.<sup>3</sup>

Date: 24 August 2023

Name of authorised officer authorising lodgement: Justin Cahill

---

<sup>1</sup> "Corporate governance statement" is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period.

Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period.

Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of Listing Rule 4.10.3.

Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council's recommendations. It also acts as a verification tool for listed entities to confirm that they have met the disclosure requirements of Listing Rule 4.10.3.

The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve different purposes and an entity must produce each of them separately.

<sup>2</sup> Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable.

<sup>3</sup> Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not applicable and just retain the option that is applicable. If you select an option that includes "OR" at the end of the selection and you delete the other options, you can also, if you wish, delete the "OR" at the end of the selection.

See notes 4 and 5 below for further instructions on how to complete this form.

## ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
<b>PRINCIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT</b>			
1.1	A listed entity should have and disclose a board charter setting out: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Responsibilities of the Board'. We have disclosed a copy of our Board Charter at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> .	–
1.2	A listed entity should: (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Director/Senior Management appointment and director election'.	–
1.3	A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Written agreements with Directors and Senior Executives'.	–

<sup>4</sup> Tick the box in this column only if you have followed the relevant recommendation **in full** for the **whole** of the period above. Where the recommendation has a disclosure obligation attached, you must insert the location where that disclosure has been made, where indicated by the line with "*insert location*" underneath. If the disclosure in question has been made in your corporate governance statement, you need only insert "our corporate governance statement". If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg "pages 10-12 of our annual report"). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg "www.entityname.com.au/corporate\_governance/charters/").

<sup>5</sup> If you have followed all of the Council's recommendations **in full** for the **whole** of the period above, you can, if you wish, delete this column from the form and re-format it.

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
1.4 The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Responsibilities of the Company Secretary'. This is reflected in our Board Charter located at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> .	-
1.5 A listed entity should: <ul style="list-style-type: none"> <li>(a) have and disclose a diversity policy;</li> <li>(b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and</li> <li>(c) disclose in relation to each reporting period:               <ul style="list-style-type: none"> <li>(1) the measurable objectives set for that period to achieve gender diversity;</li> <li>(2) the entity's progress towards achieving those objectives; and</li> <li>(3) either:                   <ul style="list-style-type: none"> <li>(A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined "senior executive" for these purposes); or</li> <li>(B) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "Gender Equality Indicators", as defined in and published under that Act.</li> </ul> </li> </ul> </li> </ul> If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Diversity objectives and achievement'. We have disclosed a copy of our Diversity Policy at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> . We have disclosed the information referred to in paragraph (c) in our Corporate Governance Statement under the heading 'Diversity objectives and achievement'.	-

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
1.6	<p>A listed entity should:</p> <p>(a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and</p> <p>(b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.</p>	<p><input checked="" type="checkbox"/></p> <p>We have disclosed the evaluation process referred to in paragraph (a) in our Corporate Governance Statement under the heading 'Board, committee and director performance'.</p> <p>We have disclosed in our Corporate Governance Statement that a performance evaluation was undertaken in accordance with that process during the reporting period.</p>	–
1.7	<p>A listed entity should:</p> <p>(a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and</p> <p>(b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.</p>	<p><input checked="" type="checkbox"/></p> <p>We have disclosed the evaluation process referred to in paragraph (a) in our Corporate Governance Statement under the heading 'CEO and senior executive performance'.</p> <p>We have disclosed in our Corporate Governance Statement that a performance evaluation was undertaken in accordance with the process during the reporting.</p>	–

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>	
<b>PRINCIPLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE</b>			
2.1	<p>The board of a listed entity should:</p> <p>(a) have a nomination committee which:</p> <p>(1) has at least three members, a majority of whom are independent directors; and</p> <p>(2) is chaired by an independent director, and disclose:</p> <p>(3) the charter of the committee;</p> <p>(4) the members of the committee; and</p> <p>(5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or</p> <p>(b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.</p>	<p><input checked="" type="checkbox"/></p> <p>Starpharma complies with paragraph (a), (1) and (2). We have disclosed details of the Remuneration and Nomination Committee in our Corporate Governance Statement under the heading 'Remuneration and Nomination Committee'.</p> <p>We have disclosed a copy of the Remuneration and Nomination Committee Charter, which is available at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a>.</p> <p>The information referred to in paragraph (4) is disclosed in our Corporate Governance Statement under the heading 'Remuneration and Nomination Committee'.</p> <p>The information referred to in paragraph (5) is disclosed in our Directors' Report (refer to Starpharma's Annual Report 2023, under the heading 'Meetings of Directors').</p>	-
2.2	A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.	<p><input checked="" type="checkbox"/></p> <p>We have disclosed our board skills matrix in our Corporate Governance Statement under the heading 'Board skills'.</p>	-
2.3	<p>A listed entity should disclose:</p> <p>(a) the names of the directors considered by the board to be independent directors;</p> <p>(b) if a director has an interest, position, affiliation or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position or relationship in question and an explanation of why the board is of that opinion; and</p> <p>(c) the length of service of each director.</p>	<p><input checked="" type="checkbox"/></p> <p>We have disclosed the names of the directors considered by the board to be independent directors (paragraph (a)) and the length of their service (paragraph (c)) in Starpharma's Annual Report 2023, under the heading 'Director/senior management appointment and director election'.</p> <p>We have disclosed the information referred to in paragraph (b) in our Corporate Governance Statement under the heading 'Directors Independence'.</p>	-

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
2.4	A majority of the board of a listed entity should be independent directors.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Directors' independence'.	–
2.5	The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Chairman and Chief Executive Officer (CEO)'.	–
2.6	A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the headings 'Board skills' and 'Director induction and professional development'.	–
<b>PRINCIPLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY</b>			
3.1	A listed entity should articulate and disclose its values.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Values' and in our Code of Conduct Policy, available at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> .	–
3.2	A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Code of conduct'. We have disclosed our Code of Conduct Policy at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> .	–
3.3	A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Whistleblower policy'. We have disclosed our Whistleblower Policy at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> .	–

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
3.4 A listed entity should: <ul style="list-style-type: none"> <li>(a) have and disclose an anti-bribery and corruption policy; and</li> <li>(b) ensure that the board or committee of the board is informed of any material breaches of that policy.</li> </ul>	<input checked="" type="checkbox"/> <p>We have disclosed this information in our Corporate Governance Statement under the heading 'Anti-bribery and corruption policy'. We have disclosed our Anti-bribery and Corruption Policy at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a>.</p>	-



## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>	
<b>PRINCIPLE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPORTS</b>			
4.1	<p>The board of a listed entity should:</p> <p>(a) have an audit committee which:</p> <p>(1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and</p> <p>(2) is chaired by an independent director, who is not the chair of the board,</p> <p>and disclose:</p> <p>(3) the charter of the committee;</p> <p>(4) the relevant qualifications and experience of the members of the committee; and</p> <p>(5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or</p> <p>(b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.</p>	<p><input checked="" type="checkbox"/></p> <p>Starpharma complies with paragraph (a), (1) and (2). We have disclosed details of the Audit and Risk Committee in our Corporate Governance Statement under the heading 'Audit and Risk Committee'.</p> <p>We have disclosed a copy of the Audit and Risk Committee Charter at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a>.</p> <p>The information referred to in paragraph (4) is in our Directors' Report (refer to Starpharma's Annual Report 2023, under the heading 'Information on Directors').</p> <p>The information referred to in paragraph (5) is in our Directors' Report (refer to Starpharma's Annual Report 2023, under the heading 'Meetings of Directors').</p>	-
4.2	<p>The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.</p>	<p><input checked="" type="checkbox"/></p> <p>We have disclosed this information in our Corporate Governance Statement under the heading 'CEO and CFO declarations for financial statements'.</p>	-

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
4.3	A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Verification process for unaudited reports'.	–
<b>PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE</b>			
5.1	A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Continuous disclosure policy'. We have disclosed our continuous disclosure compliance policy at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> .	–
5.2	A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Board promptly receives material announcements'.	–
5.3	A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Investor presentations'.	–
<b>PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS</b>			
6.1	A listed entity should provide information about itself and its governance to investors via its website.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Information on website'. We have disclosed information about us and our governance on our website at: <a href="http://www.starpharma.com/">http://www.starpharma.com/</a> and <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> .	–
6.2	A listed entity should have an investor relations program that facilitates effective two-way communication with investors.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Communication with investors'.	–

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
6.3	A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Participation at Annual General Meetings'. We have disclosed how we facilitate and encourage participation at meetings of security holders at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> (and in our Continuous Disclosure and Shareholder Communications Policy).	–
6.4	A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Voting by poll'.	–
6.5	A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Electronic communication with the company and its share registry'.	–

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>	
<b>PRINCIPLE 7 – RECOGNISE AND MANAGE RISK</b>			
7.1	<p>The board of a listed entity should:</p> <p>(a) have a committee or committees to oversee risk, each of which:</p> <p>(1) has at least three members, a majority of whom are independent directors; and</p> <p>(2) is chaired by an independent director, and disclose:</p> <p>(3) the charter of the committee;</p> <p>(4) the members of the committee; and</p> <p>(5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or</p> <p>(b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework.</p>	<p><input checked="" type="checkbox"/></p> <p>Starpharma complies with paragraph (a), (1) and (2). We have disclosed details of the Audit and Risk Committee in our Corporate Governance Statement under the heading 'Audit and Risk Committee'.</p> <p>We have disclosed a copy of the Audit and Risk Committee Charter at:</p> <p><a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a>.</p> <p>The information referred to in paragraph (4) is in our Directors' Report (refer to Starpharma's Annual Report 2023, under the heading 'Information on Directors').</p> <p>The information referred to in paragraph (5) is in our Directors' Report (refer to Starpharma's Annual Report 2023, under the heading 'Meetings of Directors').</p>	-
7.2	<p>The board or a committee of the board should:</p> <p>(a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and</p> <p>(b) disclose, in relation to each reporting period, whether such a review has taken place.</p>	<p><input checked="" type="checkbox"/></p> <p>We have disclosed this information in our Corporate Governance Statement under the heading 'Risk assessment and management'.</p> <p>We have disclosed that a review of the entity's risk management framework was undertaken during the reporting period at the reference above which can be found at:</p> <p><a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a></p>	-
7.3	<p>A listed entity should disclose:</p> <p>(a) if it has an internal audit function, how the function is structured and what role it performs; or</p> <p>(b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.</p>	<p><input checked="" type="checkbox"/></p> <p>Starpharma does not have an internal audit function.</p> <p>The processes we employ for evaluating and continually improving the effectiveness of our risk management and internal control processes is disclosed in our Corporate Governance Statement under the heading 'Internal audit function'.</p>	-

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
7.4	A listed entity should disclose whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.	<input checked="" type="checkbox"/> We have disclosed this information in our Corporate Governance Statement under the heading 'Sustainability risks and management'. We have disclosed whether we have any material exposure to environmental risks and, if we do, how we manage or intend to manage those risks at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> (please refer to our ESG Report).	–

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>	
<b>PRINCIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBLY</b>			
8.1	<p>The board of a listed entity should:</p> <p>(a) have a remuneration committee which:</p> <p>(1) has at least three members, a majority of whom are independent directors; and</p> <p>(2) is chaired by an independent director, and disclose:</p> <p>(3) the charter of the committee;</p> <p>(4) the members of the committee; and</p> <p>(5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or</p> <p>(b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.</p>	<p><input checked="" type="checkbox"/></p> <p>Starpharma complies with paragraph (a), (1) and (2). We have disclosed details of the Remuneration and Nomination Committee in our Corporate Governance Statement under the heading 'Remuneration and Nomination Committee'.</p> <p>We have disclosed a copy of the Remuneration and Nomination Committee Charter is available at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a>.</p> <p>The information referred to in paragraph (4) is disclosed in our Corporate Governance Statement under the heading 'Remuneration and Nomination Committee'.</p> <p>The information referred to in paragraph (5) is disclosed in our Directors' Report (refer to Starpharma's Annual Report 2023, under the heading 'Meetings of Directors').</p>	-
8.2	<p>A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.</p>	<p><input checked="" type="checkbox"/></p> <p>We have disclosed this information in our Corporate Governance Statement under the heading 'Non-executive and executive remuneration'.</p> <p>We have disclosed separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives in our Remuneration Report in Starpharma's Annual Report 2023.</p>	-

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <b>in full</b> for the <b>whole</b> of the period above. We have disclosed this in our Corporate Governance Statement which is located at <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> :	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
8.3	A listed entity which has an equity-based remuneration scheme should: <ul style="list-style-type: none"> <li>(a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and</li> <li>(b) disclose that policy or a summary of it.</li> </ul>	<input checked="" type="checkbox"/> <p>We have disclosed this information in our Corporate Governance Statement under the heading 'Prohibition on hedging of unvested/restricted entitlements'.</p> <p>We have disclosed our policy on this issue or a summary of it at: <a href="http://www.starpharma.com/corporate_governance">http://www.starpharma.com/corporate_governance</a> (in our Securities Dealing Policy).</p>	–
<b>ADDITIONAL RECOMMENDATIONS THAT APPLY ONLY IN CERTAIN CASES</b>			
9.1	A listed entity with a director who does not speak the language in which board or security holder meetings are held or key corporate documents are written should disclose the processes it has in place to ensure the director understands and can contribute to the discussions at those meetings and understands and can discharge their obligations in relation to those documents.	–	<input checked="" type="checkbox"/> We do not have a director in this position and this recommendation is therefore not applicable.
9.2	A listed entity established outside Australia should ensure that meetings of security holders are held at a reasonable place and time.	–	<input checked="" type="checkbox"/> We are established in Australia and this recommendation is therefore not applicable.
9.3	A listed entity established outside Australia, and an externally managed listed entity that has an AGM, should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.	–	<input checked="" type="checkbox"/> We are established in Australia and not an externally managed listed entity and this recommendation is therefore not applicable.